Immunoprecise Historical Income Statement
| IPA Stock | USD 0.38 0.03 8.57% |
Historical analysis of Immunoprecise Antibodies income statement accounts such as Total Revenue of 25.7 M or Gross Profit of 12.7 M can show how well Immunoprecise Antibodies performed in making a profits. Evaluating Immunoprecise Antibodies income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Immunoprecise Antibodies's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Immunoprecise Antibodies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunoprecise Antibodies is a good buy for the upcoming year.
Immunoprecise |
About Immunoprecise Income Statement Analysis
Immunoprecise Antibodies Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Immunoprecise Antibodies shareholders. The income statement also shows Immunoprecise investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Immunoprecise Antibodies Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Immunoprecise Antibodies generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Immunoprecise Antibodies minus its cost of goods sold. It is profit before Immunoprecise Antibodies operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Immunoprecise Antibodies. It is also known as Immunoprecise Antibodies overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Immunoprecise Antibodies' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.At present, Immunoprecise Antibodies' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 25.7 M, whereas Interest Expense is forecasted to decline to about 18.1 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 11.0M | 11.6M | 12.1M | 12.7M | Total Revenue | 19.4M | 20.7M | 24.5M | 25.7M |
Immunoprecise Antibodies income statement Correlations
Click cells to compare fundamentals
Immunoprecise Antibodies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunoprecise Antibodies income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 3.4M | 3.7M | 3.8M | 6.7M | 5.7M | 6.0M | |
| Interest Expense | 1.4M | 863K | 419K | 30K | 19K | 18.1K | |
| Total Revenue | 14.1M | 17.9M | 19.4M | 20.7M | 24.5M | 25.7M | |
| Gross Profit | 8.0M | 11.5M | 11.0M | 11.6M | 12.1M | 12.7M | |
| Other Operating Expenses | 18.1M | 22.1M | 35.5M | 48.9M | 38.3M | 40.2M | |
| Operating Income | (4.1M) | (6.7M) | (15.8M) | (26.1M) | (13.8M) | (13.1M) | |
| Ebit | (3.8M) | (5.1M) | (15.8M) | (27.7M) | (28.7M) | (27.2M) | |
| Ebitda | (366.3K) | (1.4M) | (12.0M) | (21.0M) | (22.9M) | (21.8M) | |
| Total Operating Expenses | 12.1M | 15.7M | 27.2M | 39.8M | 25.8M | 27.1M | |
| Income Before Tax | (5.3M) | (6.0M) | (15.8M) | (27.8M) | (28.7M) | (27.3M) | |
| Total Other Income Expense Net | (82.3K) | (2.1M) | (67K) | (2.1M) | (14.9M) | (14.2M) | |
| Net Income | (4.9M) | (7.3M) | (16.7M) | (26.6M) | (27.2M) | (25.8M) | |
| Income Tax Expense | (345.7K) | 1.3M | 861K | (1.2M) | (1.5M) | (1.4M) | |
| Selling General Administrative | 8.0M | 12.6M | 17.0M | 19.8M | 15.6M | 16.4M | |
| Selling And Marketing Expenses | 377.7K | 691K | 740K | 3.6M | 3.5M | 3.7M | |
| Research Development | 446.3K | 2.0M | 6.7M | 12.3M | 4.0M | 3.1M | |
| Cost Of Revenue | 6.0M | 6.4M | 8.4M | 9.1M | 12.5M | 13.1M | |
| Tax Provision | (345.7K) | 1.3M | 861K | (1.2M) | (1.5M) | (1.4M) | |
| Net Interest Income | (264.5K) | (581K) | (140K) | 240K | 4K | 4.2K | |
| Net Income From Continuing Ops | (4.9M) | (7.3M) | (16.7M) | (26.6M) | (27.2M) | (25.8M) | |
| Reconciled Depreciation | 3.4M | 3.7M | 3.8M | 6.7M | 5.7M | 3.6M | |
| Net Income Applicable To Common Shares | (4.9M) | (7.3M) | (16.7M) | (26.6M) | (23.9M) | (22.7M) | |
| Interest Income | 272.0K | 282K | 279K | 270K | 23K | 21.9K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.